



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

November 15, 2023

Neil Maresky  
Chief Executive Officer  
Psyence Biomedical Ltd.  
121 Richmond Street West  
Penthouse Suite 1300  
Toronto, Ontario M5H 2K1

**Re: Psyence Biomedical Ltd.  
Amendment No. 5 to Registration Statement on Form F-4  
Exhibit Nos. 10.5 and 10.6  
Filed November 13, 2023  
File No. 333-273553**

Dear Neil Maresky:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance